These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29637459)

  • 1. Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance.
    Haneda M; Kadowaki T; Ito H; Sasaki K; Hiraide S; Ishii M; Matsukawa M; Ueno M
    Diabetes Ther; 2018 Jun; 9(3):1083-1097. PubMed ID: 29637459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Hiraide S; Matsukawa M; Ueno M
    Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.
    Inagaki N; Nangaku M; Sakata Y; Sasaki K; Mori-Anai K; Iwasaki T; Hamada K
    Adv Ther; 2022 Jan; 39(1):674-691. PubMed ID: 34853985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T; Inagaki N; Watada H; Sasaki K; Mori-Anai K; Iwasaki T; Teranishi T
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Haneda M; Ito H; Ueno M; Matsukawa M; Yamakura T; Sasaki K; Kimura M; Iijima H
    Expert Opin Pharmacother; 2018 Feb; 19(2):83-91. PubMed ID: 29268035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: A 12-Week Interim Report.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Kim K; Lee KW
    Diabetes Ther; 2019 Aug; 10(4):1271-1282. PubMed ID: 31079357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies.
    Kadowaki T; Sasaki K; Ishii M; Matsukawa M; Ushirogawa Y
    Diabetes Ther; 2018 Apr; 9(2):623-636. PubMed ID: 29435909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teneligliptin in management of type 2 diabetes mellitus.
    Sharma SK; Panneerselvam A; Singh KP; Parmar G; Gadge P; Swami OC
    Diabetes Metab Syndr Obes; 2016; 9():251-60. PubMed ID: 27574456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in Therapy.
    Abubaker M; Mishra P; Swami OC
    J Clin Diagn Res; 2017 Jan; 11(1):OE05-OE09. PubMed ID: 28273997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
    Tobe K; Maegawa H; Nakamura I; Uno S
    Diabetol Int; 2021 Apr; 12(2):181-196. PubMed ID: 33786273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li X; Huang X; Bai C; Qin D; Cao S; Mei Q; Ye Y; Wu J
    Front Pharmacol; 2018; 9():449. PubMed ID: 29780322
    [No Abstract]   [Full Text] [Related]  

  • 14. Teneligliptin in Early Diabetic Kidney Disease: An Observation in Asian Indian Patients with Type 2 Diabetes Mellitus in Real-Life Scenario.
    Shah K
    J Clin Diagn Res; 2017 Jun; 11(6):OC22-OC25. PubMed ID: 28764219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study.
    Yamamoto F; Ikeda R; Ochiai K; Hirase T; Hayashi N; Okamura T
    Diabetes Ther; 2020 Feb; 11(2):523-533. PubMed ID: 31933070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teneligliptin Real-World Effectiveness Assessment in Patients with Type 2 Diabetes Mellitus in India: A Retrospective Analysis (TREAT-INDIA 2).
    Ghosh S; Tiwaskar M; Chawla R; Jaggi S; Asirvatham A; Panikar V
    Diabetes Ther; 2020 Oct; 11(10):2257-2268. PubMed ID: 32779100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of teneligliptin in addition to insulin therapy in type 2 diabetes mellitus patients on hemodialysis evaluated by continuous glucose monitoring.
    Yajima T; Yajima K; Hayashi M; Takahashi H; Yasuda K
    Diabetes Res Clin Pract; 2016 Dec; 122():78-83. PubMed ID: 27810689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus.
    Han E; Lee M; Lee YH; Kim HS; Lee BW; Cha BS; Kang ES
    Diabetes Metab Syndr Obes; 2020; 13():4113-4121. PubMed ID: 33173319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study.
    Kim HJ; Kim YS; Lee CB; Choi MG; Chang HJ; Kim SK; Yu JM; Kim TH; Lee JH; Ahn KJ; Min KW; Kyung EJ; Kim YK; Lee KW
    Diabetes Ther; 2021 Nov; 12(11):2907-2920. PubMed ID: 34536208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teneligliptin for the treatment of type 2 diabetes.
    Goda M; Kadowaki T
    Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.